Efficacy, tolerability and safety of long-term darifenacin treatment in older patients with overactive bladder: Analysis of results from a 2-year, open-label extension study

被引：0
|
作者：
Dwyer, P.
Lheritier, K.
Steel, M.
机构：
[1] Mercy Hosp Women, Melbourne, Vic, Australia
[2] Novartis Pharma AG, Basel, Switzerland
来源：
NEUROUROLOGY AND URODYNAMICS | 2006年 / 25卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
125
引用
收藏
页码：657 / 658
页数：2
相关论文
共 50 条
  • [1] Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study
    Haab, Francois
    Corcos, Jacques
    Siami, Paul
    Glavind, Karin
    Dwyer, Peter
    Steel, Michael
    Kawakami, Fernando
    Lheritier, Karine
    Steers, William D.
    [J]. BJU INTERNATIONAL, 2006, 98 (05) : 1025 - 1032
  • [2] Long-term treatment of overactive bladder with darifenacin in older patients: Analysis of responder rates in a 2-year, open-label extension study
    不详
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 117 - 117
  • [3] Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study
    Hill, Simon
    Elhilali, Mostafa
    Millard, Richard J.
    Dwyer, Peter L.
    Lheritier, Karine
    Kawakami, Fernando T.
    Steel, Michael
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) : 2697 - 2704
  • [4] Long-term persistence and compliance with darifenacin treatment for overactive bladder: results of a 2-year open-label extension study.
    Hill, S
    Lheritier, K
    Kawakami, F
    [J]. PHARMACOTHERAPY, 2005, 25 (10): : 1493 - 1493
  • [5] Long-term darifenacin treatment for overactive bladder: Quality of life outcomes from a 2-year, open-label extension study
    Young, J
    Lheritier, K
    Steel, M
    Dwyer, P
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A85 - A86
  • [6] QOL OUTCOMES DURING LONG-TERM TREATMENT WITH DARIFENACIN FOR OVERACTIVE BLADDER (OAB): A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Young, Jay
    Lheritier, Karine
    Steel, Michael
    Dwyer, Peter
    [J]. QUALITY OF LIFE RESEARCH, 2005, 14 (09) : 2036 - 2036
  • [7] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
  • [8] Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
    Santos, Raul D.
    Duell, P. Barton
    East, Cara
    Guyton, John R.
    Moriarty, Patrick M.
    Chin, Wai
    Mittleman, Robert S.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (09) : 566 - 575
  • [9] LONG-TERM SAFETY AND EFFICACY OF SER120 1.5 MCG IN PATIENTS WITH NOCTURIA: RESULTS FROM A 2-YEAR OPEN-LABEL EXTENSION STUDY
    MacDiarmid, Scott
    Nicandro, J. P.
    Cheng, Maria
    Abrams, Steven
    Fein, Seymour
    Wein, Alan
    [J]. JOURNAL OF UROLOGY, 2017, 197 (04): : E398 - E398
  • [10] Long-Term Safety, Tolerability and Efficacy of Flexible-Dose Fesoterodine in Elderly Patients With Overactive Bladder: Open-Label Extension of the SOFIA Trial
    Wagg, Adrian
    Khullar, Vik
    Michel, Martin C.
    Oelke, Matthias
    Darekar, Amanda
    Bitoun, Caty Ebel
    [J]. NEUROUROLOGY AND URODYNAMICS, 2014, 33 (01) : 106 - 114
12345